Genedrive appoints Matthew Fowler CFO
AIM-listed molecular diagnostic company Genedrive appointed Matthew Fowler as chief financial officer and a member of the board.
FTSE AIM All-Share
730.54
09:50 15/11/24
Genedrive
2.36p
08:27 15/11/24
Pharmaceuticals & Biotechnology
19,310.97
09:50 15/11/24
He will start at a date to be confirmed shortly and will replace John Rylands who has been with company since 2002.
Fowler joins Gendrive from Scapa Group, an AIM-listed manufacturer, where he was chief financial controller for eight years and he was previously a finance manager at British Nuclear Group. He completed training in the audit department of Deloitte & Touche.
Chief executive David Budd said Fowler’s experience in an AIM-quoted manufacturing business will be valuable to Genedrive as it matures as a commercial-stage near patient molecular diagnostics business.
He added: “I would like to reiterate the board's thanks to John Rylands for his commitment and contribution to the company over the last fourteen years, covering the period leading up to the company's listing on AIM and thereafter."
Shares in Genedrive were down 4% to 60p at 0831 BST.